Lessons learned from HIV-1 vaccine trials: new priorities and directions

Nat Immunol. 2012 Apr 18;13(5):423-7. doi: 10.1038/ni.2264.

Abstract

A vaccine against human immunodeficiency virus (HIV) seems to be on the horizon. Correlates of risk of infection for [corrected] the RV144 vaccine trial have been found. There is understanding of what makes HIV envelope-specific antibodies broadly neutralizing and new T cell vaccine approaches can overcome virus variability.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • AIDS Vaccines / immunology*
  • Animals
  • Antibodies, Neutralizing / immunology
  • Antibodies, Viral / blood
  • CD4-Positive T-Lymphocytes / immunology
  • CD8-Positive T-Lymphocytes / immunology
  • Clinical Trials as Topic
  • HIV Infections / immunology*
  • HIV Infections / prevention & control*
  • HIV-1 / immunology*
  • Humans
  • Immunoglobulin A / blood
  • Immunoglobulin G / blood
  • Macaca mulatta
  • T-Lymphocytes / immunology
  • env Gene Products, Human Immunodeficiency Virus / immunology*

Substances

  • AIDS Vaccines
  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Immunoglobulin A
  • Immunoglobulin G
  • env Gene Products, Human Immunodeficiency Virus